Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies

Orna Diav-Citrin, Svetlana Shechtman, Judy Arnon, Asher Ornoy

Research output: Contribution to journalArticlepeer-review

80 Scopus citations

Abstract

The Israeli Teratogen Information Service prospectively followed up 210 pregnancies with first trimester carbamazepine exposure. Pregnancy outcome was compared with that of two overlapping controls, matched and general (n = 629), exposed to nonteratogenic agents. Our study suggests a twofold increase in the rate of major congenital anomalies (12/160 [carbamazepine] versus 18/560 [general control]; relative risk 2.24; 95% CI 1.1-4.56) and a birth weight reduction of approximately 250 g after in utero exposure to carbamazepine.

Original languageEnglish
Pages (from-to)321-324
Number of pages4
JournalNeurology
Volume57
Issue number2
DOIs
StatePublished - 24 Jul 2001
Externally publishedYes

Fingerprint

Dive into the research topics of 'Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies'. Together they form a unique fingerprint.

Cite this